These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9611090)

  • 1. Comparison of venlafaxine and imipramine in depressive illness.
    Rajagopalan M
    Acta Psychiatr Scand; 1998 May; 97(5):384-5. PubMed ID: 9611090
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia.
    Benkert O; Gründer G; Wetzel H; Hackett D
    J Psychiatr Res; 1996; 30(6):441-51. PubMed ID: 9023787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Is there a relationship between clinical efficacy and antidepressant dosage in major depression?].
    Corruble E; Guelfi JD
    Encephale; 1999 Jun; 25 Spec No 2():39-43; discussion 44-6. PubMed ID: 10434158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of venlafaxine in depressive illness in general practice.
    Lecrubier Y; Bourin M; Moon CA; Schifano F; Blanchard C; Danjou P; Hackett D
    Acta Psychiatr Scand; 1997 Jun; 95(6):485-93. PubMed ID: 9242843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical use of venlafaxine serology to uncover genetic rapid metabolism.
    Schaller JL; Behar D
    J Neuropsychiatry Clin Neurosci; 2001; 13(1):112-3. PubMed ID: 11207339
    [No Abstract]   [Full Text] [Related]  

  • 6. Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine.
    Dallal A; Chouinard G
    J Clin Psychopharmacol; 1998 Aug; 18(4):343-4. PubMed ID: 9690703
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antidepressant treatment associated hyponatremia -- case report].
    Bognár Z; Vonyik G; Gazdag G
    Neuropsychopharmacol Hung; 2013 Sep; 15(3):177-80. PubMed ID: 24108183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithium augmentation of venlafaxine in adolescent major depression.
    Walter G; Lyndon B; Kubb R
    Aust N Z J Psychiatry; 1998 Jun; 32(3):457-9. PubMed ID: 9672738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients.
    Charlier C; Pinto E; Ansseau M; Plomteux G
    J Psychopharmacol; 2002 Dec; 16(4):369-72. PubMed ID: 12503838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venlafaxine: new preparation. Just another antidepressant.
    Prescrire Int; 1998 Aug; 7(36):112-4. PubMed ID: 10342950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buspirone as an antidote to venlafaxine-induced bruxism.
    Jaffee MS; Bostwick JM
    Psychosomatics; 2000; 41(6):535-6. PubMed ID: 11110119
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
    Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T; Keller M
    Int Clin Psychopharmacol; 2008 Nov; 23(6):357-63. PubMed ID: 18854724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy.
    Lauritzen L; Odgaard K; Clemmesen L; Lunde M; Ohrström J; Black C; Bech P
    Acta Psychiatr Scand; 1996 Oct; 94(4):241-51. PubMed ID: 8911559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia.
    Gentil V; Kerr-Correa F; Moreno R; D'Arrigo Busnello E; De Campos JA; Juruena MF; Lafer B; Moreno DH; De Cassia Rodrigues RL; Tiosso A; Benedictis E
    J Psychopharmacol; 2000 Mar; 14(1):61-6. PubMed ID: 10757255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venlafaxine monotherapy in women with bipolar II and unipolar major depression.
    Amsterdam JD; Garcia-España F
    J Affect Disord; 2000 Sep; 59(3):225-9. PubMed ID: 10854639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
    Rush AJ; Wisniewski SR; Warden D; Luther JF; Davis LL; Fava M; Nierenberg AA; Trivedi MH
    Arch Gen Psychiatry; 2008 Aug; 65(8):870-80. PubMed ID: 18678792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortisol level in men with major depressive disorder treated with fluoxetine or imipramine.
    Piwowarska J; Dryll K; Szelenberger W; Pachecka J
    Acta Pol Pharm; 2008; 65(1):159-64. PubMed ID: 18536191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modafinil-induced reversible hyperkinetic nondystonic movement disorder in a patient with major depressive disorder.
    Luborzewski A; Regen F; Schindler F; Anghelescu I
    J Neuropsychiatry Clin Neurosci; 2006; 18(2):248-9. PubMed ID: 16720809
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of bupropion with SRIs and venlafaxine.
    Spier SA
    Depress Anxiety; 1998; 7(2):73-5. PubMed ID: 9614595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venlafaxine plus mirtazapine as first-line treatment for melancholia: preliminary results.
    Ruiz-Doblado S; Rueda-Villar T; Zurita-Gotor P; Sanz-Cortes S
    J Psychopharmacol; 2010 Dec; 24(12):1837. PubMed ID: 21138931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.